Main Menu


The Institute of Cancer Research currently has a number of partnering and licensing opportunities and any member of the Enterprise Unit would be pleased to review these with potential commercial collaborators.

Glypican-5, a novel cancer target

ICR collaboration and licensing opportunity.
Principal Scientists:  Dr Janet Shipley

GPC5 has been identified as a potential therapeutic target in soft tissue sarcoma, breast carcinoma, lung carcinoma, lymphoma, medulloblastoma and glioblastoma. This target is amenable to antibody mediated therapies. It also has potential as a biomarker.

For further information contact Jonathan Beech or download the PDF flyer.


Jonathan Beech Business Development Manager
Paul Carnochan Senior Business Development Manager

Connections newsletter

Sign up to our new quarterly newsletter for updates on our Enterprise Unit and news about working with industry.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.